1.42
                                            
                                Überblick
                                Nachrichten
                                Preisverlauf
                                    Optionskette
                                Financials
                                    Warum fällt LXRX?
                                Forum
                                Prognose
                                    Aktiensplit
                        
                        Schlusskurs vom Vortag:
              $1.40
            Offen:
              $1.42
            24-Stunden-Volumen:
                1.01M
            Relative Volume:
              0.42
            Marktkapitalisierung:
                $516.03M
            Einnahmen:
              $1.21M
            Nettoeinkommen (Verlust:
              $-177.12M
            KGV:
              -1.775
            EPS:
                -0.8
            Netto-Cashflow:
                $-162.37M
            1W Leistung:
              +0.00%
            1M Leistung:
              +6.77%
            6M Leistung:
                +101.88%
            1J Leistung:
              -22.83%
            Lexicon Pharmaceuticals Inc Stock (LXRX) Company Profile
Firmenname
                  
                      Lexicon Pharmaceuticals Inc
                    
                Sektor
                  Branche
                  Telefon
                  
                      (281) 863-3000
                    
                Adresse
                  
                      2445 TECHNOLOGY FOREST BLVD., THE WOODLANDS
                    
                Vergleichen Sie LXRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV | 
|---|---|---|---|---|---|---|
|   
                          
                                LXRX
                            
                             Lexicon Pharmaceuticals Inc | 1.42 | 508.76M | 1.21M | -177.12M | -162.37M | -0.80 | 
|   
                          
                                VRTX
                            
                             Vertex Pharmaceuticals Inc | 421.39 | 108.36B | 11.39B | 3.64B | 3.50B | 13.99 | 
|   
                          
                                ALNY
                            
                             Alnylam Pharmaceuticals Inc | 463.43 | 60.82B | 2.46B | -319.09M | -52.09M | -2.4669 | 
|   
                          
                                REGN
                            
                             Regeneron Pharmaceuticals Inc | 577.95 | 61.02B | 14.21B | 4.46B | 3.56B | 39.69 | 
|   
                          
                                ARGX
                            
                             Argen X Se Adr | 817.32 | 50.01B | 3.06B | 1.28B | 447.35M | 19.67 | 
|   
                          
                                ONC
                            
                             Beone Medicines Ltd Adr | 310.81 | 34.05B | 4.56B | -176.77M | 225.30M | -1.7177 | 
Lexicon Pharmaceuticals Inc Stock (LXRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung | 
|---|---|---|---|
| 2025-03-05 | Herabstufung | Leerink Partners | Outperform → Market Perform | 
| 2024-06-17 | Eingeleitet | H.C. Wainwright | Buy | 
| 2024-04-30 | Eingeleitet | Leerink Partners | Outperform | 
| 2023-03-07 | Eingeleitet | Jefferies | Hold | 
| 2022-08-12 | Eingeleitet | Piper Sandler | Overweight | 
| 2021-01-29 | Hochstufung | JP Morgan | Underweight → Neutral | 
| 2021-01-29 | Herabstufung | Wedbush | Outperform → Neutral | 
| 2020-12-08 | Hochstufung | Citigroup | Neutral → Buy | 
| 2020-11-18 | Hochstufung | Gabelli & Co | Hold → Buy | 
| 2019-12-11 | Herabstufung | Gabelli & Co | Buy → Hold | 
| 2019-11-08 | Herabstufung | Citigroup | Buy → Neutral | 
| 2019-09-11 | Hochstufung | Gabelli & Co | Hold → Buy | 
| 2019-07-29 | Herabstufung | Stifel | Buy → Hold | 
| 2019-03-25 | Hochstufung | Gabelli & Co | Sell → Hold | 
| 2018-07-31 | Bestätigt | Stifel | Buy | 
| 2018-02-23 | Herabstufung | Needham | Buy → Hold | 
| 2018-02-14 | Herabstufung | JP Morgan | Neutral → Underweight | 
| 2017-03-01 | Bestätigt | H.C. Wainwright | Buy | 
| 2017-03-01 | Bestätigt | Wedbush | Outperform | 
| 2016-10-07 | Eingeleitet | H.C. Wainwright | Buy | 
| 2016-08-05 | Bestätigt | Wedbush | Outperform | 
| 2016-08-02 | Eingeleitet | Citigroup | Buy | 
| 2016-03-02 | Bestätigt | Wedbush | Outperform | 
| 2015-11-09 | Bestätigt | Wedbush | Outperform | 
| 2015-09-28 | Hochstufung | Gabelli & Co | Sell → Hold | 
| 2015-09-18 | Herabstufung | Gabelli & Co | Hold → Sell | 
| 2015-08-10 | Herabstufung | JP Morgan | Overweight → Neutral | 
                    Alle ansehen
                     
                  
                Lexicon Pharmaceuticals Inc Aktie (LXRX) Neueste Nachrichten
Is Lexicon Pharmaceuticals Inc. stock attractive for growth ETFsJuly 2025 Institutional & Consistent Profit Alerts - newser.com
What candlestick patterns are forming on Lexicon Pharmaceuticals Inc.Market Sentiment Review & Free High Return Stock Watch Alerts - newser.com
Is Lexicon Pharmaceuticals Inc. stock attractive for hedge fundsQuarterly Profit Summary & Weekly High Return Forecasts - newser.com
Using data tools to time your Lexicon Pharmaceuticals Inc. exitJuly 2025 Outlook & Technical Pattern Alert System - newser.com
Published on: 2025-10-24 01:54:11 - newser.com
Is Lexicon Pharmaceuticals Inc. building a consolidation baseDip Buying & Safe Swing Trade Setups - newser.com
Published on: 2025-10-21 14:44:52 - newser.com
Full technical analysis of Lexicon Pharmaceuticals Inc. stockEntry Point & Safe Entry Zone Tips - newser.com
What analysts say about Lexicon Pharmaceuticals Inc stockTrading Volume Trends & Double Or Triple Investment - earlytimes.in
Macro Review: Is Lexicon Pharmaceuticals Inc. stock a defensive play in 20252025 Market Overview & Comprehensive Market Scan Reports - nchmf.gov.vn
How analysts rate Lexicon Pharmaceuticals Inc. stock todayWeekly Trend Recap & Long-Term Growth Stock Strategies - nchmf.gov.vn
Activity Recap: How analysts rate Lexicon Pharmaceuticals Inc. stock todayJuly 2025 EndofMonth & Community Trade Idea Sharing - nchmf.gov.vn
Is Lexicon Pharmaceuticals Inc. stock a defensive play in 20252025 Pullback Review & AI Optimized Trading Strategy Guides - nchmf.gov.vn
Lexicon Pharmaceuticals Inc Stock Analysis and ForecastSector Leadership Analysis & Affordable Growth Strategies - earlytimes.in
Lexicon Pharmaceuticals Presents Additional Pilavapadin Data in Diabetic Peripheral Neuropathic Pain at 19th Annual Pain Therapeutics Summit - The Manila Times
Lexicon Pharmaceuticals Advances 10mg Pilavapadin to Phase 3 | LXRX Stock News - Stock Titan
Short interest data insights for Lexicon Pharmaceuticals Inc.2025 Geopolitical Influence & AI Enhanced Trading Signals - newser.com
Lexicon Pharmaceuticals (NASDAQ:LXRX) Trading 8% HigherWhat's Next? - MarketBeat
Lexicon Pharmaceuticals' (LXRX) "Sell (D-)" Rating Reiterated at Weiss Ratings - MarketBeat
Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Price Down 6.3%Time to Sell? - MarketBeat
Lexicon (LXRX) Engages in Policy Discussion to Tackle Chronic Pa - GuruFocus
Lexicon Pharmaceuticals Hosts Roundtable on Legislative Solutions for Chronic Pain Management - Quiver Quantitative
Lexicon Pharmaceuticals Convenes Roundtable to Address Public Policy Gaps for People with Chronic Pain - MarketScreener
Lexicon Pharmaceuticals Convenes Roundtable to Address Public Policy Gaps for People With Chronic Pain - 富途牛牛
Detecting price anomalies in Lexicon Pharmaceuticals Inc. with AIEarnings Beat & Intraday High Probability Alerts - newser.com
Can you recover from losses in Lexicon Pharmaceuticals Inc.2025 Analyst Calls & Safe Entry Point Identification - newser.com
Is Lexicon Pharmaceuticals Inc. a candidate for recovery playPortfolio Value Summary & Consistent Income Trade Recommendations - newser.com
Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Finanzdaten der Lexicon Pharmaceuticals Inc-Aktie (LXRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
        In Yahoo öffnen
        |
        In Google öffnen
            |
            In Finviz öffnen
        |
        In MarketWatch öffnen
            |
            Öffnen Sie in EDGAR    
        |
        Offen in Reuters
    
    
                Kapitalisierung:
                 
                  | 
                Volumen (24h):
                 
            
         
                     
                             Holen Sie sich die Stockscreener-App
                    Holen Sie sich die Stockscreener-App